Autolus Therapeutics (AUTL) Q2 2026 earnings

Published Aug 11, 2026

AI summary

Revenue $45.7M, up 118% from $20.9M a year ago.
GAAP EPS −$0.15 beat the −$0.19 consensus by $0.04, up from −$0.18 a year ago.
Autolus reported Q2 2026 net product revenue of $45.7 million, a 119% increase compared to the prior year.
The company's gross margin improved to 55% in Q2 2026, up from 6% in the previous quarter.
Net loss for the quarter narrowed to $39.1 million, compared to a $47.9 million loss in the same period last year.

Revenue

Reported

$45.7M

Consensus not captured before release

+118% YoY

EPS · GAAP (street basis)

Reported · Diluted EPS (GAAP, street basis)

−$0.15

Consensus −$0.19

Beat by $0.04

GAAP EPS: −$0.15

Consensus: Yahoo Finance · Q2 2026 · EPS estimate at release
Revenue display rounded; difference uses exact result.

$140M–$150M

fiscal 2026 revenue guidance

Next-quarter consensus not captured before release.

The company implemented a 13% workforce reduction in April 2026 to reduce operating expenses.
The company's cash and marketable securities decreased to $201.6 million from $229.4 million at the end of Q1.

Source: Autolus Therapeutics plc press release · SEC Form 8-K exhibit 99.1

Figures as stated in the company’s release; consensus from the provider named above. Not financial advice.